Leland Gershell
Stock Analyst at Oppenheimer
(4.25)
# 359
Out of 4,784 analysts
127
Total ratings
37.93%
Success rate
25.08%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Initiates: Outperform | $10 | $1.35 | +640.74% | 1 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $12 → $20 | $6.50 | +207.69% | 3 | Mar 11, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $704 | $589.15 | +19.49% | 6 | Feb 28, 2025 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $98 | $71.44 | +37.18% | 3 | Feb 24, 2025 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Outperform | $76 | $54.80 | +38.69% | 1 | Dec 20, 2024 | |
| ASND Ascendis Pharma | Maintains: Outperform | $190 → $180 | $154.68 | +16.37% | 10 | Nov 15, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $48 → $52 | $19.99 | +160.13% | 2 | Nov 11, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $135 → $147 | $107.62 | +36.59% | 2 | Nov 8, 2024 | |
| VERU Veru Inc. | Reiterates: Outperform | $5 | $0.51 | +884.06% | 8 | Nov 5, 2024 | |
| EPIX ESSA Pharma | Downgrades: Perform | n/a | $1.56 | - | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $73 | $71.99 | +1.40% | 8 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $11.20 | +257.14% | 9 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $18.37 | +188.51% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $35.11 | - | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $43 | $11.50 | +273.91% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $4.30 | +597.67% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $1.48 | +710.81% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $25 | $1.28 | +1,853.13% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 → $28 | $14.44 | +93.91% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $4.58 | +445.85% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $34.73 | +110.19% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $1.99 | +905.03% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $24.69 | +17.46% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $8.46 | +313.71% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.92 | +986.96% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $5.58 | -10.39% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.26 | +1,487.30% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $268.46 | - | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $0.88 | +1,377.27% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $0.25 | +1,500.00% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.22 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $360,000 | $1.56 | +23,076,823.08% | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $15.08 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.15 | +2,228.40% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $0.44 | - | 5 | Mar 31, 2020 |
Quince Therapeutics
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $1.35
Upside: +640.74%
Trevi Therapeutics
Mar 11, 2025
Maintains: Outperform
Price Target: $12 → $20
Current: $6.50
Upside: +207.69%
argenx SE
Feb 28, 2025
Maintains: Outperform
Price Target: $675 → $704
Current: $589.15
Upside: +19.49%
BioMarin Pharmaceutical
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $71.44
Upside: +37.18%
Rhythm Pharmaceuticals
Dec 20, 2024
Initiates: Outperform
Price Target: $76
Current: $54.80
Upside: +38.69%
Ascendis Pharma
Nov 15, 2024
Maintains: Outperform
Price Target: $190 → $180
Current: $154.68
Upside: +16.37%
Dianthus Therapeutics
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $19.99
Upside: +160.13%
Ligand Pharmaceuticals
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $107.62
Upside: +36.59%
Veru Inc.
Nov 5, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.51
Upside: +884.06%
ESSA Pharma
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $1.56
Upside: -
Oct 28, 2024
Maintains: Outperform
Price Target: $65 → $73
Current: $71.99
Upside: +1.40%
Oct 16, 2024
Reiterates: Outperform
Price Target: $40
Current: $11.20
Upside: +257.14%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $18.37
Upside: +188.51%
Oct 3, 2024
Initiates: Perform
Price Target: n/a
Current: $35.11
Upside: -
Sep 25, 2024
Maintains: Outperform
Price Target: $15 → $43
Current: $11.50
Upside: +273.91%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $4.30
Upside: +597.67%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $1.48
Upside: +710.81%
Sep 3, 2024
Maintains: Outperform
Price Target: $150 → $25
Current: $1.28
Upside: +1,853.13%
Aug 12, 2024
Reiterates: Outperform
Price Target: $31 → $28
Current: $14.44
Upside: +93.91%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $4.58
Upside: +445.85%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $34.73
Upside: +110.19%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $1.99
Upside: +905.03%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $24.69
Upside: +17.46%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $8.46
Upside: +313.71%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.92
Upside: +986.96%
Mar 28, 2024
Initiates: Outperform
Price Target: $5
Current: $5.58
Upside: -10.39%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.26
Upside: +1,487.30%
Oct 11, 2023
Downgrades: Perform
Price Target: n/a
Current: $268.46
Upside: -
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $0.88
Upside: +1,377.27%
Mar 24, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $0.25
Upside: +1,500.00%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.22
Upside: -
Jun 4, 2021
Initiates: Outperform
Price Target: $360,000
Current: $1.56
Upside: +23,076,823.08%
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $15.08
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $2.15
Upside: +2,228.40%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $0.44
Upside: -